Policy & Regulation
Hemispherian secures US patent allowance expanding GLIX1 patent protection
19 November 2025 - Norwegian biotechnology company Hemispherian AS announced on Wednesday that the US Patent and Trademark Office has issued a Notice of Allowance for its patent application covering u...
Mycovia Pharmaceuticals publishes long-term efficacy results from extension study of VIVJOA
19 November 2025 - Biopharmaceutical company Mycovia Pharmaceuticals Inc announced on Tuesday that long-term efficacy results from an extension study of the VIOLET Phase 3 clinical programme, which ev...
AbbVie receives approval for EPKINLY, rituximab and lenalidomide combination
19 November 2025 - US-based pharmaceutical company AbbVie (NYSE:ABBV) announced on Tuesday that it has received approval from the US Food and Drug Administration for EPKINLY (epcoritamab-bysp), a T-ce...
European Commission approves Insmed's BRINSUPRI for the treatment of non-cystic fibrosis bronchiectasis
18 November 2025 - US-based biopharmaceutical company Insmed Incorporated (Nasdaq: INSM) said on Tuesday that the European Commission has approved BRINSUPRI (brensocatib 25mg tablets) for patients wit...
Genentech reports first oral SERD to improve invasive disease-free survival in early breast cancer
18 November 2025 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), announced on Tuesday that its Phase III lidERA trial of giredestrant met its primary endp...
Biotheryx completes enrolment in ongoing Phase 1a trial of BTX-9341 for HR+/HER2- breast cancer
18 November 2025 - Biotheryx Inc, a biopharmaceutical company focused on the discovery and development of first-in-class protein degraders for cancer and inflammatory diseases, on Monday announced the...